专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0198530A3 INTERACTION OF TBX2 AND THE ARF PROMOTER IN CELL CYCLE REGULATOR ASSAYS 审中-公开
标题翻译： TBX2和ARF促进剂在细胞周期调节剂测定中的相互作用
公开(公告)号：WO0198530A3
公开(公告)日：2003-01-16
申请号：PCT/GB0102706
申请日：2001-06-19
申请人： VERENIGING HET NL KANKER I , PROLIFIX LTD , VAN LOHUIZEN MAARTEN , JACOBS JACQUELINE , VAN DE VIJVER MARC
发明人： VAN LOHUIZEN MAARTEN , JACOBS JACQUELINE , VAN DE VIJVER MARC
IPC分类号： G01N33/574 , G01N33/68
CPC分类号： G01N33/57415 , G01N33/6872
摘要： The present invention provides an assay for a modulator of cell cycle progression, which comprises: a) bringing into contact a TBX2 protein, an ARF promoter TBX-2 binding region and a putative inhibitor compound under conditions where the TBX2 protein and the binding region, in the absence of inhibitor, are capable of forming a complex; and b) measuring the degree of inhibition of binding or transcriptional activation caused by said inhibitor compound.The invention further provides a method for the diagnosis or prognosis of breast cancer which method comprises determining the amount of TBX2 nucleic acid or protein in a cell which cell is, or is suspected to be, a breast tumour cell or metastatic cell from a breast tumour.
摘要翻译：本发明提供了一种细胞周期进程调节剂的测定法，其包括：a）在TBX2蛋白和结合区域的条件下，使TBX2蛋白，ARF启动子TBX-2结合区和推定的抑制剂化合物接触，在没有抑制剂的情况下，能够形成复合物; 和b）测量由所述抑制剂化合物引起的结合或转录激活的抑制程度。本发明还提供了一种用于诊断或预后的乳腺癌的方法，该方法包括测定细胞中TBX2核酸或蛋白质的量是或怀疑是来自乳腺肿瘤的乳腺肿瘤细胞或转移性细胞。

2. 发明申请

WO2006071843A3 BIOMARKERS FOR BREAST CANCER 审中-公开
标题翻译：乳腺癌生物标志物
公开(公告)号：WO2006071843A3
公开(公告)日：2009-04-23
申请号：PCT/US2005047005
申请日：2005-12-27
申请人： VERENIGING HET NL KANKER I , PODUST VLADIMIR , BEIJNEN JACOB HENDRIK , GAST MARIE-CHRISTINE WILLEMINE , HARRIS NATHAN
发明人： PODUST VLADIMIR , BEIJNEN JACOB HENDRIK , GAST MARIE-CHRISTINE WILLEMINE , HARRIS NATHAN
IPC分类号： A61K38/00 , C07K5/00 , C07K16/00 , C12Q1/00 , G01N33/53
CPC分类号： G01N33/57415
摘要： The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. For example, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.
摘要翻译：本发明提供了可用于评估患者乳腺癌状态的基于蛋白质的生物标志物和生物标志物组合。例如，本发明的生物标志物可用于将受试者样品分类为乳腺癌或非乳腺癌。生物标志物可以通过SELDI质谱检测。

3. 发明申请

WO2005074995A2 COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS 审中-公开
标题翻译： PRAME抑制剂和HDAC抑制剂的组合使用
公开(公告)号：WO2005074995A2
公开(公告)日：2005-08-18
申请号：PCT/EP2005000937
申请日：2005-01-27
申请人： VERENIGING HET NL KANKER I , BERNARDS RENE , EPPING MIRJAM , WANG LIMING
发明人： BERNARDS RENE , EPPING MIRJAM , WANG LIMING
IPC分类号： A61K31/16 , A61K31/203 , A61K45/06 , A61K48/00 , C12N15/113
CPC分类号： A61K31/7088 , A61K31/16 , A61K31/18 , A61K31/203 , A61K45/06 , A61K48/00 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2320/31 , A61K2300/00
摘要： The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.
摘要翻译：本发明涉及癌抗原PRAME（MElanoma中PRELY表达的抗原）及其在治疗肿瘤的方法中的应用，其包括向需要治疗的受试者施用有效量的PRAME抑制剂，与第二选自HDAC抑制剂（HDACi）和类视黄醇类的药剂。

4. 发明申请

WO2004064711A2 MODULATION OF DEUBIQUITINASE FAMILY MEMBERS 审中-公开
标题翻译：调查家庭成员
公开(公告)号：WO2004064711A2
公开(公告)日：2004-08-05
申请号：PCT/EP2004000408
申请日：2004-01-16
申请人： VERENIGING HET NL KANKER I , BERNARDS RENE , BRUMMELKAMP THIJN R , DIRAC ANNETTE M , NIJMAN SEBASTIAN M
发明人： BERNARDS RENE , BRUMMELKAMP THIJN R , DIRAC ANNETTE M , NIJMAN SEBASTIAN M
IPC分类号： A61K20060101 , A61K48/00 , C12N15/113 , C12Q1/48 , G01N33/50 , G01N33/574 , G01N33/68 , A61K
CPC分类号： G01N33/5011 , A61K48/00 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Q1/485 , G01N33/5008 , G01N33/5041 , G01N33/57407 , G01N33/68 , G01N33/6842 , G01N33/6872 , G01N33/6893
摘要： Modulation of Deubiquitinase Family Members The present invention relates to the therapeutic treatment of conditions by modulating members of the deubiquitinase family, and also to assays for identifying substances which may be useful in such treatments, as well as to the treatment of cylindromatosis and more generally to the modulation of other conditions associated with activation of the transcription factor NF-KB, such as inflammation.
摘要翻译：去泛素酶家族成员的调节本发明涉及通过调节去泛素酶家族成员的条件的治疗性治疗，以及用于鉴定可用于这种治疗的物质的测定，以及治疗圆锥形病变，更通常地说与转录因子NF-κB活化相关的其他条件的调节，如炎症。

5. 发明申请

WO2008026075A3 TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS WITH A PROTEIN KINASE INHIBITOR OR AN AS160 POLYPEPTIDE ACTIVATOR 审中-公开
标题翻译：用蛋白激酶抑制剂或AS160多肽激活剂治疗细菌性细菌感染
公开(公告)号：WO2008026075A3
公开(公告)日：2009-01-22
申请号：PCT/IB2007003553
申请日：2007-08-31
申请人： VERENIGING HET NL KANKER I , ACADEMISCH ZIEKENHUIS LEIDEN , UNIV LEIDEN , NEEFJES JACQUES JACOBUS , OVERKLEEFT HERMAN STEVEN , OTTENHOFF THOMAS HENRICUS MARI , SAVAGE NIGEL DENNING LEONARD , TUIN ADRIAAN WILLEM , MARSMAN MARIJE , KUIJL COENRAAD PAUL
发明人： NEEFJES JACQUES JACOBUS , OVERKLEEFT HERMAN STEVEN , OTTENHOFF THOMAS HENRICUS MARIA , SAVAGE NIGEL DENNING LEONARD , TUIN ADRIAAN WILLEM , MARSMAN MARIJE , KUIJL COENRAAD PAUL
IPC分类号： A61K31/00 , A61K31/472 , A61K31/7088 , A61K38/02 , A61K38/16 , A61K38/17 , A61K45/06 , A61P31/04 , C07D217/02 , C07D217/06 , C12N15/113 , G01N33/569
CPC分类号： C12N15/1137 , A61K31/00 , A61K31/33 , A61K31/472 , A61K31/7088 , C07D217/02 , C12Q1/485 , G01N2500/02 , A61K2300/00
摘要： Products for treating intracellular bacterial infections comprising a protein kinase inhibitor and/or an activator of AS160 polypeptide-. The protein kinase inhibitor may be a H-89 derivative.
摘要翻译：用于治疗细胞内细菌感染的产品，其包含蛋白激酶抑制剂和/或AS160多肽的活化剂。蛋白激酶抑制剂可以是H-89衍生物。

6. 发明申请

WO0185992A3 ASSAY FOR CELL CYCLE MODULATORS 审中-公开
标题翻译：细胞周期调节剂的测定
公开(公告)号：WO0185992A3
公开(公告)日：2002-05-23
申请号：PCT/GB0102099
申请日：2001-05-14
申请人： PROLIFIX LTD , VERENIGING HET NL KANKER I , BERNARDS RENE , AGAMI REUVEN
发明人： BERNARDS RENE , AGAMI REUVEN
IPC分类号： G01N33/50 , G01N33/68 , C12Q1/68
CPC分类号： G01N33/5011 , G01N33/6872
摘要： The present invention relates to the finding that cyclin D1 is targeted for destruction in cells which have been exposed to ionising radiation (IR). This finding gives rise to an assay for modulators of cell cycle control, which assay comprises: (a) providing a cell in culture together with apotential modulator compound, said cell expressing a cyclin D1 which undergoes degradation in response to DNAdamage; (b) exposing said cell to a DNA damaging agent; and (c) determining the extent to which the presence of the potential modulator compound inhibits the degradation of said cyclin D1.This finding further gives rise to an assay for modulators of cell cycle control, which assay comprises: (a) providing a cyclin D1, the APC or a componentthereof which interacts with cyclin D1, together with apotential modulator compound; and (b) determining the extent to which the presence of thepotential modulator compound inhibits the interaction ofsaid cyclin D1 and APC or component thereof. In particular where the component of the APC is a protein cdc20.
摘要翻译：本发明涉及细胞周期蛋白D1在已经暴露于电离辐射（IR）的细胞中被破坏的发现。该发现引起细胞周期调控调节剂的测定，该测定法包括：（a）提供培养物中的细胞与潜力调节剂化合物，所述细胞表达细胞周期蛋白D1，其响应于DNA损伤而进行降解; （b）将所述细胞暴露于DNA损伤剂; 并且（c）确定潜在的调节剂化合物的存在程度抑制所述细胞周期蛋白D1的降解。该发现进一步导致细胞周期调控调节剂的测定，该测定包括：（a）提供细胞周期蛋白D1 ，APC或其与细胞周期蛋白D1相互作用的组分，以及潜力调节剂化合物; 和（b）确定潜在调节剂化合物的存在抑制细胞周期蛋白D1和APC或其组分的相互作用的程度。特别是在APC的组分是蛋白质cdc20的情况下。

7. 发明申请

WO2009027644A8 COMPOSITION 审中-公开
标题翻译：组成
公开(公告)号：WO2009027644A8
公开(公告)日：2009-04-30
申请号：PCT/GB2008002854
申请日：2008-08-22
申请人： VERENIGING HET NL KANKER I , SLOTERVAART PARTICIPATIES BV , JONES NICHOLAS ANDREW , BEIJNEN JACOB HENDRIK , SCHELLENS JOHANNES HENRICUS MATTHIAS , MOES JOHANNES , NUIJEN BASTIAAN
发明人： BEIJNEN JACOB HENDRIK , SCHELLENS JOHANNES HENRICUS MATTHIAS , MOES JOHANNES , NUIJEN BASTIAAN
IPC分类号： A61K9/14 , A61K9/19 , A61K9/48 , A61K31/337 , A61K31/426 , A61K45/06 , A61P35/00
CPC分类号： A61K9/146 , A61K9/19 , A61K9/4858 , A61K31/337 , A61K31/426 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical compositions and methods for the treatment of neoplastic disease and comprising the combination of a taxane, such as docetaxel, with a CYP3A4 inhibitor, such as ritonavir. Methods of treatment of neoplastic disease incorporating the administration of a taxane and the administration of a CYP3A4 inhibitor, either simultaneously or separately, are also included. Further, kits for carrying out the methods are included. Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant are also included.
摘要翻译：用于治疗肿瘤疾病并包含紫杉烷如多西紫杉醇与CYP3A4抑制剂如利托那韦的组合的药物组合物和方法。还包括同时或分别施用紫杉烷和施用CYP3A4抑制剂的肿瘤疾病的治疗方法。此外，还包括用于执行方法的套件。还包括用于口服给药的固体药物紫杉烷组合物，其包含基本上无定形的紫杉烷，载体和表面活性剂。

8. 发明专利

GB0713192D0 Anti-tumour methods 未知
公开(公告)号：GB0713192D0
公开(公告)日：2007-08-15
申请号：GB0713192
申请日：2007-07-06
申请人： VERENIGING HET NL KANKER I
摘要： There is provided a use of a DSB repair-inhibitor in the manufacture of a medicament for use in the treatment of a cancer in an individual, wherein the cancer comprises cells which are/is deficient in a BER and/or a SSBR pathway.

9. 发明专利

AT351918T 未知
公开(公告)号：AT351918T
公开(公告)日：2007-02-15
申请号：AT01938473
申请日：2001-06-19
申请人： VERENIGING HET NL KANKER I
发明人： VAN LOHUIZEN MAARTEN , JACOBS JACQUELINE , VAN DE VIJVER MARC
IPC分类号： G01N33/574 , G01N33/68 , C12Q1/00

10. 发明专利

GB0700281D0 Methods and Means for the Treatment of Cancer 未知
公开(公告)号：GB0700281D0
公开(公告)日：2007-02-14
申请号：GB0700281
申请日：2007-01-08
申请人： VERENIGING HET NL KANKER I

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式